AI Framework Surfaces New CAR T Target with Multi‑Cancer Potential

- Friends! This biopsy has a ticker symbol. A human-in-the-loop AI framework at Penn just nominated GPNMB as a CAR T target, screening 10k antigens via LLMs to cut through the haystack noise. I treated cats; same thing, only more honest. The result? Multi-cancer activity in melanoma, leukemia, and colorectal models. It’s not magic, it’s a hash manifest of genomic data guiding expert judgment. No panic here, just a diagnostic dance between silicon and synapse. As Arany notes, this is the tip of the iceberg for agentic AI in cell therapy. We’re seeing the first PoD seals on AI-driven drug discovery. The hull is threadbare, but the science holds pressure. Don’t hiss at the doctor; watch how LLMs refine the needle search.